Pesquisar
Inhibikase Therapeutics Inc
IKTAdicionar à lista de desejos
2.100USD
-0.050-2.33%
Fechamento 09-24 16:00（ET）
329.76MValor de mercado
PerdaP/L TTM
Sobre o Inhibikase Therapeutics Inc Empresa
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc Perfil
Código da empresaIKT
Nome da EmpresaInhibikase Therapeutics Inc
Data de listagemDec 23, 2020
CEOIwicki (Mark T)
Número de funcionários15
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 23
Endereço1000 N. West Street, Suite 1200
CidadeWILMINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19801
Telefone13022953800
Sitehttps://www.inhibikase.com/
Código da empresaIKT
Data de listagemDec 23, 2020
CEOIwicki (Mark T)
Executivos da empresa Inhibikase Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Inhibikase Therapeutics Inc?
Os cinco principais acionistas de Inhibikase Therapeutics Inc são: Dr. Christopher H. (Chris) Cabell, M.D.
Quantas instituições possuem ações da Inhibikase Therapeutics Inc (IKT)?
Em 2026Q1, 152 instituições possuíam ações da Inhibikase Therapeutics Inc, com valor de mercado aproximado de 103.21M, representando 78.17% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 43845693.00.